Andy Burnham announces £48m partnership in bid to 'defeat' dementia
Key takeaway
£48m dementia research partnership pools government, pharma and philanthropic capital to de-risk early-stage drug development
- Step 1 · The triggergovernment commits £33m to match pharma/philanthropic funding for dementia research, creating de-risked R&D pools
- Step 2 · Knock-onBristol Myers Squibb and GSK secure privileged access to UK clinical trial infrastructure and the planned Health Data Research Service
- Step 3 · Knock-onaccelerated trial timelines and data-driven target validation improve probability of technical success for dementia drug candidates
- Step 4 · Knock-onexpanded trial activity generates subcontracting demand for UK clinical research organisations, site management and patient recruitment services
- Step 5 · Reaches youthe SME supplier's order book and revenue visibility improve as pharma procurement flows through to specialist service contracts
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: independent.co.uk
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.